Renewed commitment of the German Government to neglected diseases

KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi

DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.

“Towards Ending the Neglect?” DNDi releases update on its Paediatric HIV Programme

[July 2016]
As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing ‘4-in-1’ fixed-dose combinations using the World Health Organization (WHO) recommended treat­ment regimen for infants and young chil­dren. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).

AusTrade supports Epichem leishmaniasis research programme

DNDi and its partner Epichem are pleased to announce that the Australian Tropical Medicine Commercialisation Grants Programme (ATMCG), with the support of Australia’s Trade and Investment Ministry (AusTrade), are providing $250,000 for a project which is focused on developing new treatments for leishmaniasis. The name of the project is: “Novel compounds for the treatment of Leishmaniasis in humans and animals,” which will be led by PharmAust Limited’s (ASX:PAA) subsidiary Epichem in partnership with DNDi.

Malaria: New research promises to ease access to ASAQ and ASMQ treatment

Access to effective treatment is central in the fight against malaria. The recently published PREGACT study has shown that artemisinin-based combination therapies are effective in pregnant women with malaria in Africa, without the safety concerns of other treatment types. Another success for malaria treatment comes with the World Health Organization’s announcement that the fixed-dose combination of artesunate+mefloquine (ASMQ) shelf-life has been extended from two to three years, which will greatly help with storage and distribution.

Call for papers for PLOS WorldLeish-6 Collection

Dr Jorge Alvar, Head of Leishmaniasis, DNDi, and Dr Javier Moreno, Director of WHO Collaborating Center for Leishmaniasis, announce a call for papers on Leishmaniasis for the PLOS WorldLeish-6 Collection. See the PLOS article, calling for papers for the PLOS WorldLeish 6 Collection, as it appeared on the PLOS Blog.

Hepatitis C: Current barriers to treat patients and DNDi’s R&D strategy to address urgent needs

Hepatitis C Infographic - DNDi Project

DNDi, Pharco, and the Ministry of Health Malaysia announced today at the International Liver Congress in Barcelona, Spain, that they signed agreements to test an affordable hepatitis C regimen in Malaysia and Thailand. The treatment, a potentially pan-genotypic combination of ravidasvir and sofosbuvir, will be tested in Malaysia and Thailand with a target price of under $300. DNDi also released its hepatitis C R&D Strategy as well as infographics to explain why there are so many neglected hepatitis C patients.

R&D status November 2015: DNDi Filarial diseases programme

[November 2015]

Filarial diseases are caused by parasitic worms of the helminth family. They include onchocerciasis (also known as River Blindness), lymphatic filariasis (also known as elephantiasis), and loiasis (also known as African eye-worm). The worms are transmitted by insect vectors to humans, mainly in Africa and Southeast Asia. About 168 million people are infected by the three diseases.

R&D status November 2015: DNDi Sleeping Sickness programme

[November 2015]
Human African trypanosomiasis (HAT), also known as ‘sleeping sickness’, is transmitted by the bite of a tsetse fly. While currently its prevalence is declining, 21 million people are still at risk across 36 Sub-Saharan Africa countries with most of the cases occurring in the Democratic Republic of Congo (89% of all cases in 2013).

R&D status November 2015: DNDi Leishmaniasis programme

[November 2015]
The parasite that causes leishmaniasis is transmitted by the bite of a sandfly. Leishmaniasis is a complex group of diseases with over a million new cases occurring every year and 350 million people living at risk worldwide in 98 countries. The most common forms of the disease are visceral leishmaniasis (VL), which is fatal without treatment, and cutaneous leishmaniasis (CL).